JP2025128343A5 - - Google Patents
Info
- Publication number
- JP2025128343A5 JP2025128343A5 JP2025100129A JP2025100129A JP2025128343A5 JP 2025128343 A5 JP2025128343 A5 JP 2025128343A5 JP 2025100129 A JP2025100129 A JP 2025100129A JP 2025100129 A JP2025100129 A JP 2025100129A JP 2025128343 A5 JP2025128343 A5 JP 2025128343A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- sequence number
- cdr2
- cdr3
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785659P | 2018-12-27 | 2018-12-27 | |
| US62/785,659 | 2018-12-27 | ||
| PCT/US2019/068820 WO2020140084A1 (en) | 2018-12-27 | 2019-12-27 | Anti-ctla-4 binding proteins and methods of use thereof |
| JP2021537082A JP7558949B2 (ja) | 2018-12-27 | 2019-12-27 | 抗ctla-4結合タンパク質およびその使用方法 |
| JP2024014900A JP7745669B2 (ja) | 2018-12-27 | 2024-02-02 | 抗ctla-4結合タンパク質およびその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014900A Division JP7745669B2 (ja) | 2018-12-27 | 2024-02-02 | 抗ctla-4結合タンパク質およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025128343A JP2025128343A (ja) | 2025-09-02 |
| JP2025128343A5 true JP2025128343A5 (cg-RX-API-DMAC7.html) | 2026-03-18 |
| JP7854093B2 JP7854093B2 (ja) | 2026-04-30 |
Family
ID=71126610
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537082A Active JP7558949B2 (ja) | 2018-12-27 | 2019-12-27 | 抗ctla-4結合タンパク質およびその使用方法 |
| JP2024014900A Active JP7745669B2 (ja) | 2018-12-27 | 2024-02-02 | 抗ctla-4結合タンパク質およびその使用方法 |
| JP2025100129A Active JP7854093B2 (ja) | 2018-12-27 | 2025-06-16 | 抗ctla-4結合タンパク質およびその使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537082A Active JP7558949B2 (ja) | 2018-12-27 | 2019-12-27 | 抗ctla-4結合タンパク質およびその使用方法 |
| JP2024014900A Active JP7745669B2 (ja) | 2018-12-27 | 2024-02-02 | 抗ctla-4結合タンパク質およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12421311B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3902821A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7558949B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102970393B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN114008071B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019413366B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021012588A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3124961C (cg-RX-API-DMAC7.html) |
| IL (2) | IL284156B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021007848A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202106764YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020140084A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7296728B2 (ja) * | 2015-10-23 | 2023-06-23 | メルス ナムローゼ フェンノートシャップ | 癌の成長を抑制する結合分子 |
| CN114008071B (zh) | 2018-12-27 | 2025-01-21 | 吉加根公司 | 抗ctla-4结合蛋白及其使用方法 |
| US20230265192A1 (en) * | 2020-07-02 | 2023-08-24 | Gigagen, Inc. | Anti-ctla-4 binding proteins and methods of use thereof |
| JP2024502035A (ja) * | 2020-12-31 | 2024-01-17 | ノヴァロック バイオセラピューティクス, リミテッド | Tnfr2に対する抗体およびそれの使用 |
| AU2022303528A1 (en) * | 2021-07-02 | 2024-01-25 | Gigagen, Inc. | Anti-ctla-4 binding proteins and methods of use thereof |
| MX2024007054A (es) * | 2021-12-10 | 2024-09-04 | Merck Sharp & Dohme Llc | Aglutinantes de mesotelina humana. |
| WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) * | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US20110166335A1 (en) | 2000-06-30 | 2011-07-07 | Corbin David R | Xenorhabdus sp. genome sequences and uses thereof |
| TWI320716B (en) * | 2002-10-14 | 2010-02-21 | Abbott Lab | Erythropoietin receptor binding antibodies |
| WO2006029219A2 (en) * | 2004-09-08 | 2006-03-16 | Ohio State University Research Foundation | Human monoclonal anti-ctla4 antibodies in cancer treatment |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| SMT201900242T1 (it) * | 2012-12-03 | 2019-05-10 | Bristol Myers Squibb Co | Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici |
| WO2015092394A1 (en) | 2013-12-17 | 2015-06-25 | Kymab Limited | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
| PL3151921T3 (pl) * | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| CN114014930A (zh) * | 2015-02-13 | 2022-02-08 | 索伦托药业有限公司 | 结合ctla4的抗体治疗剂 |
| HRP20201334T1 (hr) | 2015-04-17 | 2020-11-27 | Bristol-Myers Squibb Company | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| DK3303394T3 (da) * | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| AU2016370648B2 (en) * | 2015-12-15 | 2023-03-09 | OncoC4, Inc. | Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof |
| SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| NL2017270B1 (en) * | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
| MX2019010156A (es) | 2017-02-27 | 2020-01-09 | Dragonfly Therapeutics Inc | Proteínas multiespecíficas de unión de direccionamiento a anhidrasa carbónica 9 (caix), anoctamina-1 (ano1), mesotelina, antígeno de superficie celular de trofoblasto (trop2), antígeno carcinoembrionario (cea) o claudina-18.2. |
| IL270743B2 (en) * | 2017-05-19 | 2024-09-01 | Wuxi Biologics Shanghai Co Ltd | Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| CN114008071B (zh) | 2018-12-27 | 2025-01-21 | 吉加根公司 | 抗ctla-4结合蛋白及其使用方法 |
| AU2020210614A1 (en) | 2019-01-21 | 2021-08-26 | Sanofi | Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers |
| US20230265192A1 (en) | 2020-07-02 | 2023-08-24 | Gigagen, Inc. | Anti-ctla-4 binding proteins and methods of use thereof |
-
2019
- 2019-12-27 CN CN201980092796.9A patent/CN114008071B/zh active Active
- 2019-12-27 KR KR1020217023740A patent/KR102970393B1/ko active Active
- 2019-12-27 US US17/418,776 patent/US12421311B2/en active Active
- 2019-12-27 CN CN202510014877.4A patent/CN119930820A/zh active Pending
- 2019-12-27 EP EP19902920.8A patent/EP3902821A4/en active Pending
- 2019-12-27 IL IL284156A patent/IL284156B2/en unknown
- 2019-12-27 CA CA3124961A patent/CA3124961C/en active Active
- 2019-12-27 JP JP2021537082A patent/JP7558949B2/ja active Active
- 2019-12-27 KR KR1020267016339A patent/KR20260085344A/ko active Pending
- 2019-12-27 WO PCT/US2019/068820 patent/WO2020140084A1/en not_active Ceased
- 2019-12-27 IL IL316757A patent/IL316757A/en unknown
- 2019-12-27 SG SG11202106764YA patent/SG11202106764YA/en unknown
- 2019-12-27 MX MX2021007848A patent/MX2021007848A/es unknown
- 2019-12-27 CA CA3249127A patent/CA3249127A1/en active Pending
- 2019-12-27 AU AU2019413366A patent/AU2019413366B2/en active Active
- 2019-12-27 BR BR112021012588-4A patent/BR112021012588A2/pt unknown
-
2024
- 2024-02-02 JP JP2024014900A patent/JP7745669B2/ja active Active
-
2025
- 2025-06-16 JP JP2025100129A patent/JP7854093B2/ja active Active
- 2025-08-27 AU AU2025223772A patent/AU2025223772A1/en active Pending
- 2025-08-27 US US19/312,203 patent/US20260125474A1/en active Pending